Recent Updates — PAVM

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., closed a private placement on October 21, 2026, selling 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share. The transaction generated gross proceeds of $15.0 million for the subsidiary. Investors received registration rights to facilitate the resale of common stock issuable upon conversion of the preferred shares. PAVmed Inc. operates in the medical device industry.

PAVmed Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 9, 2026, establishing an at-the-market equity offering program. The company may sell up to $9,400,000 of common stock through the agent, paying a 3.0% commission plus legal reimbursement fees capped at $65,000 for execution and quarterly amounts thereafter. Net proceeds are intended for working capital and general corporate purposes. PAVmed Inc. operates in the medical device industry, developing minimally invasive treatments for venous disease.

At its annual meeting on June 24, 2026, PAVmed Inc. stockholders approved amendments to the Employee Stock Purchase Plan (ESPP), increasing the total shares available from 15,774 to 215,774 and raising the annual evergreen provision limit from 5,556 to 500,000 shares. Stockholders also re-elected Ronald M. Sparks and Timothy Baxter as Class A directors and ratified CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company operates in the healthcare industry, developing medical devices and technologies.